449 related articles for article (PubMed ID: 20380793)
1. [Polymerase region mutations and hepatitis B virus genotypes in chronic hepatitis B patients with poor response to lamivudine].
Xu LJ; Pan C; Li QG; Chen RH; Zheng L; Zhang QY; Chen HC
Zhonghua Gan Zang Bing Za Zhi; 2010 Mar; 18(3):180-3. PubMed ID: 20380793
[TBL] [Abstract][Full Text] [Related]
2. Differences of YMDD mutational patterns, precore/core promoter mutations, serum HBV DNA levels in lamivudine-resistant hepatitis B genotypes B and C.
Pan XP; Li LJ; Du WB; Li MW; Cao HC; Sheng JF
J Viral Hepat; 2007 Nov; 14(11):767-74. PubMed ID: 17927612
[TBL] [Abstract][Full Text] [Related]
3. [Identification of factors associated with YMDD mutation in patients with chronic hepatitis B receiving lamivudine treatment].
Cao XX; Li J; Qiu LM; Luo YW; Chen YH; Ran Y
Zhonghua Gan Zang Bing Za Zhi; 2009 Sep; 17(9):641-4. PubMed ID: 19785947
[TBL] [Abstract][Full Text] [Related]
4. Frequent detection of hepatitis B virus variants associated with lamivudine resistance in treated South African patients infected chronically with different HBV genotypes.
Selabe SG; Song E; Burnett RJ; Mphahlele MJ
J Med Virol; 2009 Jun; 81(6):996-1001. PubMed ID: 19382250
[TBL] [Abstract][Full Text] [Related]
5. [Entecavir resistance in entecavir naive lamivudine treated chronic hepatitis B patients].
Sayan M; Hülagü S; Akhan SC; Sentürk O; Meriç M; Cekmen M
Mikrobiyol Bul; 2009 Jul; 43(3):425-32. PubMed ID: 19795617
[TBL] [Abstract][Full Text] [Related]
6. [Genotype distribution of chronic hepatitis B and hepatitis C patients and investigation of the resistance patterns in hepatitis B cases].
Kalayci R; Altindiş M; Gülamber G; Demirtürk N; Akcan Y; Demirdal T
Mikrobiyol Bul; 2010 Apr; 44(2):237-43. PubMed ID: 20549958
[TBL] [Abstract][Full Text] [Related]
7. Response to long-term lamivudine treatment (up to 5 years) in patients with severe chronic hepatitis B, role of genotype and drug resistance.
Moskovitz DN; Osiowy C; Giles E; Tomlinson G; Heathcote EJ
J Viral Hepat; 2005 Jul; 12(4):398-404. PubMed ID: 15985011
[TBL] [Abstract][Full Text] [Related]
8. [Effects comparison of lamivudine therapy for hepatitis B virus genotypes B and C].
Zhou JL; Wu SP
Zhonghua Gan Zang Bing Za Zhi; 2004 Aug; 12(8):489-90. PubMed ID: 15329211
[TBL] [Abstract][Full Text] [Related]
9. Genotype prevalence, viral load and outcome of hepatitis B virus precore mutant infection in stable patients and in patients after liver transplantation.
Ben-Ari Z; Ashur Y; Daudi N; Shmilovitz-Wiess H; Brown M; Sulkes J; Klein A; Mor E; Tur-Kaspa R; Shouval D
Clin Transplant; 2004 Aug; 18(4):415-22. PubMed ID: 15233819
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis B virus genotypes and hepatitis B surface antigen mutations in family contacts of hepatitis B virus infected patients with occult hepatitis B virus infection.
Kumar GT; Kazim SN; Kumar M; Hissar S; Chauhan R; Basir SF; Sarin SK
J Gastroenterol Hepatol; 2009 Apr; 24(4):588-98. PubMed ID: 19207682
[TBL] [Abstract][Full Text] [Related]
11. [Detection and analysis of the new kind of G743C and G743A point mutation of HBV P gene in hepatitis B virus infected patients resistant to lamivudine].
Pan XP; Wo JE; Chen Z; Chen F; Liang WF; Liu KZ
Zhonghua Gan Zang Bing Za Zhi; 2003 Oct; 11(10):616-8. PubMed ID: 14572341
[TBL] [Abstract][Full Text] [Related]
12. [Evaluation of a quantitative HBV-DNA PCR assay in lamivudine treated hepatitis B-infected patients].
Deal C; Ajana F; Canva V; Mouton Y; Yazdanpanah Y; Wattré P; Bocket L
Ann Biol Clin (Paris); 2002; 60(5):581-8. PubMed ID: 12368144
[TBL] [Abstract][Full Text] [Related]
13. Association between lamivudine sensitivity and the number of substitutions in the reverse transcriptase region of the hepatitis B virus polymerase.
Fukai K; Zhang KY; Imazeki F; Kurihara T; Mikata R; Yokosuka O
J Viral Hepat; 2007 Sep; 14(9):661-6. PubMed ID: 17697019
[TBL] [Abstract][Full Text] [Related]
14. Occult hepatitis B virus infection and lamivudine-resistant mutations in isolates from renal patients undergoing hemodialysis.
Motta JS; Mello FC; Lago BV; Perez RM; Gomes SA; Figueiredo FF
J Gastroenterol Hepatol; 2010 Jan; 25(1):101-6. PubMed ID: 19817965
[TBL] [Abstract][Full Text] [Related]
15. [A clinical study of viral dynamic change in patients with hepatitis B e antigen positive chronic hepatitis B by lamivudine treatment].
Xu JH; Yu YY; Si CW; Chen XY; Han ZH; Chen Y; Li XY
Zhonghua Yi Xue Za Zhi; 2009 Nov; 89(41):2902-5. PubMed ID: 20137646
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B virus genotypes B and C do not affect the antiviral response to lamivudine.
Yuen MF; Wong DK; Sablon E; Yuan HJ; Sum SM; Hui CK; Chan AO; Wang BC; Lai CL
Antivir Ther; 2003 Dec; 8(6):531-4. PubMed ID: 14760886
[TBL] [Abstract][Full Text] [Related]
17. Prevalence and clinical characterization of patients with acute hepatitis B induced by lamivudine-resistant strains.
Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Yoshioka K; Yano M; Toyoda H; Kumada T; Goto H
J Gastroenterol Hepatol; 2010 Apr; 25(4):745-9. PubMed ID: 20074155
[TBL] [Abstract][Full Text] [Related]
18. Significance of viral load, core promoter/precore mutations and specific sequences of polymerase gene in HBV-infected patients on 3-year lamivudine treatment.
Yuen MF; Sablon E; Libbrecht E; Van De Velde H; Wong DK; Fung J; Wong BC; Lai CL
Antivir Ther; 2006; 11(6):779-86. PubMed ID: 17310822
[TBL] [Abstract][Full Text] [Related]
19. [A real-time PCR assay for the quantification of hepatitis B virus DNA and concurrent detection of YMDD motif mutations].
Ağca H; Sayıner AA; Sengönül A; Simşek I; Akarsu M
Mikrobiyol Bul; 2011 Oct; 45(4):664-76. PubMed ID: 22090297
[TBL] [Abstract][Full Text] [Related]
20. Comparison of mass spectrometric analysis and TRUGENE HBV genotyping for monitoring lamivudine resistance in chronic hepatitis B patients.
Woo HY; Park H; Kim BI; Jeon WK; Cho YK; Kim YJ
Antivir Ther; 2007; 12(1):7-13. PubMed ID: 17503742
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
